Guo M, Chan THM, Zhou Q, An O, Li Y, Song Y, Tan ZH, Ng VHE, Peramangalam PS, Tan ZQ, Cao X, Iwanaga E, Matsuoka M, Ooi MGM, Jen WY, Koh LP, Chan E, Tan LK, Goh Y, Wang W, Koh BTH, Chun CM, Fullwood MJ, Chng WJ, Osato M, Pulikkan JA, Yang H, Chen L, Tenen DG.

Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis.

Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K.

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.

Tatetsu H, Higuchi Y, Shichijo T, Oda K, Nakata H, Yasunaga JI, Nosaka K, Matsuoka M.

Prophylactic effect of tixagevimab-cilgavimab on COVID-19 infection and death in Japanese patients with B cell lymphoma.

Sakurada-Aono M, Sakamoto T, Kobayashi M, Takiuchi Y, Iwai F, Tada K, Sasanuma H, Hirabayashi S, Murakawa Y, Shirakawa K, Sakamoto C, Shindo K, Yasunaga JI, Matsuoka M, Pommier Y, Takeda S, Takaori-Kondo A.

HTLV-1 bZIP factor impairs DNA mismatch repair system.

Shichijo T, Tatetsu H, Nosaka K, Higuchi Y, Kikukawa Y, Toyoda K, Shiraishi S, Yasunaga JI, Matsuoka M.

Robust prognostic value of histologic transformation in patients with early progression of follicular lymphoma.

Sakurada-Aono M, Sakamoto T, Kobayashi M, Takiuchi Y, Iwai F, Tada K, Sasanuma H, Hirabayashi S, Murakawa Y, Shirakawa K, Sakamoto C, Shindo K, Yasunaga JI, Matsuoka M, Pommier Y, Takeda S, Takaori-Kondo A.

HTLV-1 bZIP factor impairs DNA mismatch repair system.

Biochem Biophys Res Commun 21:657:43-49,2023. doi: 10.1016/j.bbrc.2023.03.049.

https://pubmed.ncbi.nlm.nih.gov/36972660/

Beauvois A, Gazon H, Chauhan PS, Jamakhani M, Jacques JR, Thiry M, Dejardin E, Valentin ED, Twizere JC, Péloponèse JM, Njock MS, Yasunaga JI, Matsuoka M, Hamaïdia M, Willems L.

The helicase-like transcription factor redirects the autophagic flux and restricts human T cell leukemia virus type 1 infection.

https://pubmed.ncbi.nlm.nih.gov/37487091/

Tsuchiya S, Takaku T, Watanabe N, Iriyama N, Kimura Y, Iwanaga E, Sugimoto KJ, Mitsumori T, Ishikawa M, Nakazato T, Fujita H, Sato E, Hatta Y, Asou N, Kizaki M, Tokuhira M, Ando M, Kawaguchi T.

Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.

Tatetsu H, Watanabe M, Liu J, Tokunaga K, Iwanaga E, Komohara Y, Thrash E, Bassal MA, Matsuoka M, Tenen DG, Chai L.

Dissecting the cell of origin of aberrant SALL4 expression in myelodysplastic syndrome.

Clin Transl Med13(8):e1327,2023.doi: 10.1002/ctm2.1327.

https://pubmed.ncbi.nlm.nih.gov/37501279/

Furuta R, Tatetsu H, Yasunaga JI, Ueno M, Oshiro K, Kumanomido S, Kawano Y, Higuchi Y, Honda Y, Mikami Y, Nosaka K, Matsuoka M.

Waldenstrom’s macroglobulinemia-like B cell lymphoma with MYD88 L265P mutation and t(14;18)(q32;q21) involving IGH-MALT1.

Toyoda K, Yasunaga JI, Shichijo T, Arima Y, Tsujita K, Tanaka A, Salah T, Zhang W, Hussein O, Sonoda M, Watanabe M, Kurita D, Nakashima K, Yamada K, Miyoshi H, Ohshima K, Matsuoka M.

HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion.

https://pubmed.ncbi.nlm.nih.gov/37162520/

Hiramatsu H, Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, Imaizumi Y, Hidaka M, Sasaki H, Makiyama J, Ohtsuka E, Jo T, Ogata M, Ito A, Yonekura K, Tatetsu H, Kato T, Kawakita T, Suehiro Y, Ishitsuka K, Iida S, Matsutani T, Nishikawa H, Utsunomiya A, Ueda R, Ishida T.

Landscape of immunoglobulin heavy chain γ gene class switch recombination in patients with adult T-cell leukemia-lymphoma.

Haematologica 1;108(4):1173-1178.doi: 10.3324/haematol.2022.281435.

https://pubmed.ncbi.nlm.nih.gov/36420800/

Oda K, Yamaguchi A, Matsumoto N, Nakata H, Higuchi Y, Nosaka K, Jono H, Saito H.

Dose Individualization of Cefepime for Febrile Neutropenia in Patients With Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring.